Shattuck Labs (NASDAQ:STTK) Issues Quarterly Earnings Results

Shattuck Labs (NASDAQ:STTK) announced its quarterly earnings results on Thursday. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.04), FiscalAI reports.

Shattuck Labs Stock Performance

Shares of STTK stock traded down $0.66 during mid-day trading on Thursday, hitting $4.49. The company’s stock had a trading volume of 1,434,725 shares, compared to its average volume of 971,046. The stock has a market cap of $450.62 million, a price-to-earnings ratio of -8.80 and a beta of 1.21. Shattuck Labs has a 52-week low of $1.72 and a 52-week high of $8.33. The business has a 50-day moving average price of $6.13 and a 200 day moving average price of $6.02.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on STTK. Leerink Partners began coverage on Shattuck Labs in a report on Monday, July 20th. They set an “outperform” rating and a $16.00 target price on the stock. UBS Group began coverage on Shattuck Labs in a research note on Sunday, October 11th. They issued a “buy” rating and a $17.00 target price for the company. JPMorgan Chase & Co. initiated coverage on Shattuck Labs in a research report on Friday, July 24th. They set an “overweight” rating and a $10.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Shattuck Labs in a research note on Friday, September 11th. Finally, HC Wainwright reduced their price target on Shattuck Labs from $18.00 to $14.00 and set a “buy” rating on the stock in a research note on Tuesday, August 11th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $13.70.

About Shattuck Labs

Shattuck Labs, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The company’s research is based on its Agonist Redirected Checkpoint (ARC) platform, which is designed to combine immune-cell activation with checkpoint inhibition in a single therapeutic molecule.

Shattuck’s pipeline has included bifunctional fusion proteins such as SL-172154, an investigational therapy designed to engage CD40 ligand and block PD-L1, and SL-173154, which is designed to target CD27 ligand and PD-L1.